This is a global non-interventional registry-based, post-authorization study (PASS) in paediatric and adult patients who have received Luxturna® sub-retinal injections in a real-world setting. Patients will be treated according to the local prescribing information and routine medical practice. The study will collect all AEs and SAEs including AEs of special interest (AESIs), information about pregnancy occurrence and outcomes, and ophthalmic examination results. A five year enrolment duration is expected to provide a minimum of 40 participants who are to be followed annually for 5 years.